Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathological Tau transmission initiated by binding lymphocyte-activation gene 3.
Chen C, Kumbhar R, Wang H, Yang X, Gadhave K, Rastegar C, Kimura Y, Behensky A, Katakam S, Jeong D, Wang L, Wang A, Chen R, Zhang S, Jin L, Workman CJ, Vignali DAA, Pletinkova O, Nauen DW, Wong PC, Troncoso JC, Ying M, Dawson VL, Dawson TM, Mao X. Chen C, et al. Among authors: katakam s. bioRxiv [Preprint]. 2023 May 17:2023.05.16.541015. doi: 10.1101/2023.05.16.541015. bioRxiv. 2023. PMID: 37293032 Free PMC article. Updated. Preprint.
Lymphocyte-Activation Gene 3 Facilitates Pathological Tau Neuron-to-Neuron Transmission.
Chen C, Kumbhar R, Wang H, Yang X, Gadhave K, Rastegar C, Kimura Y, Behensky A, Kotha S, Kuo G, Katakam S, Jeong D, Wang L, Wang A, Chen R, Zhang S, Jin L, Workman CJ, Vignali DAA, Pletinkova O, Jia H, Peng W, Nauen DW, Wong PC, Redding-Ochoa J, Troncoso JC, Ying M, Dawson VL, Dawson TM, Mao X. Chen C, et al. Among authors: katakam s. Adv Sci (Weinh). 2024 Apr;11(16):e2303775. doi: 10.1002/advs.202303775. Epub 2024 Feb 7. Adv Sci (Weinh). 2024. PMID: 38327094 Free PMC article.
A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial.
Verstovsek S, Talpaz M, Wadleigh M, Isidori A, Te Boekhorst P, Savona MR, Bose P, Pozdnyakova O, Mesa R, El-Galaly TC, O'Sullivan J, Gamel K, Higgins B, Katakam S, Todorov B, Trunzer K, Harrison CN. Verstovsek S, et al. Among authors: katakam s. Haematologica. 2024 Jan 25. doi: 10.3324/haematol.2023.284410. Online ahead of print. Haematologica. 2024. PMID: 38268448 Free article.
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study.
Mascarenhas J, Passamonti F, Burbury K, El-Galaly TC, Gerds A, Gupta V, Higgins B, Wonde K, Jamois C, Kovic B, Huw LY, Katakam S, Maffioli M, Mesa R, Palmer J, Bellini M, Ross DM, Vannucchi AM, Yacoub A. Mascarenhas J, et al. Among authors: katakam s. Blood Adv. 2022 Feb 22;6(4):1162-1174. doi: 10.1182/bloodadvances.2021006043. Blood Adv. 2022. PMID: 34933330 Free PMC article. Clinical Trial.
Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.
Morschhauser F, Ghosh N, Lossos IS, Palomba ML, Mehta A, Casasnovas O, Stevens D, Katakam S, Knapp A, Nielsen T, McCord R, Salles G. Morschhauser F, et al. Among authors: katakam s. Blood Cancer J. 2021 Aug 20;11(8):147. doi: 10.1038/s41408-021-00539-8. Blood Cancer J. 2021. PMID: 34417444 Free PMC article. Clinical Trial.
19 results